| 1 |
32997383 | Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma. | 2021 Jan |
2 |
| 2 |
33419772 | HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer. | 2021 Mar 15 |
1 |
| 3 |
33750801 | A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. | 2021 Mar 9 |
1 |
| 4 |
34258514 | The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells. | 2021 Aug |
2 |
| 5 |
32371576 | Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. | 2020 Jul |
3 |
| 6 |
32882003 | Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. | 2020 Sep 8 |
2 |
| 7 |
31559706 | The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. | 2019 Nov 7 |
1 |